Titan America's initial public offering was priced toward the low end of expectations, giving the U.S. arm of Belgian cement producer Titan Cement International an initial market value of about $2.95 billion.

Cystic-fibrosis-focused Sionna Therapeutics made its public debut this week, with an upsized public offering. Meanwhile, Titan America had a

Titan America (TTAM), a subsidiary of Titan Cement International and parent company of its U.S. operations, priced its IPO of 24M shares at a price to the public of $16.00 per share. The IPO consists of 9M new common shares to be issued and sold by Titan America and 15M existing shares to be sold by Titan Cement International SA.